Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Oct;143(2):261-7.
doi: 10.1111/j.1365-2141.2008.07320.x. Epub 2008 Aug 28.

Shortened intensified multi-agent chemotherapy and non-cross resistant maintenance therapy for advanced lymphoblastic lymphoma in children and adolescents: report from the Children's Oncology Group

Minnie Abromowitch  1 , Richard Sposto, Sherrie Perkins, David Zwick, Stuart Siegel, Jonathan Finlay, Mitchell S Cairo; Children's Oncology Group
Affiliations

Shortened intensified multi-agent chemotherapy and non-cross resistant maintenance therapy for advanced lymphoblastic lymphoma in children and adolescents: report from the Children's Oncology Group

Minnie Abromowitch et al. Br J Haematol. 2008 Oct.

Abstract

Pediatric lymphoblastic lymphoma (LL) has utilized treatment strategies similar to childhood acute lymphoblastic leukaemia (ALL) with prolonged maintenance chemotherapy. We report the results of a pilot study to estimate the feasibility, toxicity and efficacy of a 12-month aggressive multi-agent chemotherapy regimen in children and adolescents with advanced LL. Between July 1994 and June 1997, 85 eligible children and adolescents with advanced LL (Stage III/IV) were enrolled on this pilot study. Patients achieving a complete response following induction and consolidation received six cycles of maintenance chemotherapy for a total duration of 12 months. Grade III/IV toxicities included: hematological (80%), infections (20%), stomatitis and elevated transaminases, (29%). There were a total of 19 events, 13 relapses, two secondary acute myeloid leukaemia and four toxic deaths (5%). The 5-year event-free survival (EFS) and overall survival (OS) was 78 +/- 4.5% and 85 +/- 3.9%, respectively. Relapsed patients had a 5-year OS of only 33 +/- 14%. Multivariate analysis failed to demonstrate age, gender, lactate dehydrogenase level, presence of marrow and/or central nervous system disease to have independent prognostic value. These results suggest that this experimental approach is safe and results in similar outcomes as more prolonged childhood ALL regimens.

PubMed Disclaimer

Figures

Figure One
Figure One. Event-Free Survival and Survival from Study Entry
Probability of event free survival (EFS) and overall survival (OS) of all patients from diagnosis.
Figure Two
Figure Two. Event-free survival by age at diagnosis
Comparison of event free survival (EFS) stratified by age groups 0–4 years ( ———— ), 5–9 years ( --------- ), 10+ years (-.-.-.- -.- )of all patients from diagnosis. (p=0.17, logrank test for homogeneity, p=0.63, logrank test for trend)
See this image and copyright information in PMC

References

    1. Anderson JR, Jenkin RD, Wilson JF, Kjeldsberg CR, Sposto R, Chilcote RR, Coccia PF, Exelby PR, Siegel S, Meadows AT, et al. Long-term follow-up of patients treated with COMP or LSA2L2 therapy for childhood non-Hodgkin's lymphoma: a report of CCG-551 from the Childrens Cancer Group. J Clin Oncol. 1993;11:1024–1032. - PubMed
    1. Anderson JR, Wilson JF, Jenkin DT, Meadows AT, Kersey J, Chilcote RR, Coccia P, Exelby P, Kushner J, Siegel S, Hammond D. Childhood non-Hodgkin's lymphoma. The results of a randomized therapeutic trial comparing a 4-drug regimen (COMP) with a 10-drug regimen (LSA2-L2) N Engl J Med. 1983;308:559–565. - PubMed
    1. Bergeron C, Celine S, Pacquement H, Perel Y, Coze C, Gandemer V, Vannier JP, Mechinaud F, Schmitt C, Leverger G, Baruchel A, Perol D, Patte C. Childhood T-cell lymphoblastic lymphoma (TLL) results of the SFOP LMT96 strategy. Pediatr Blood Cancer. 2006;46:867a.
    1. Burkhardt B, Bruch J, Salzburg J, Zimmermann M, Reiter A. Clinical and biological significance of loss of heterozygosity at chromosome 6q in children and adolescents with T-cell lymphoblastic lymphoma. Pediatr Blood Cancer. 2006a;46:840a.
    1. Burkhardt B, Woessmann W, Zimmermann M, Kontny U, Vormoor J, Doerffel W, Mann G, Henze G, Niggli F, Ludwig WD, Janssen D, Riehm H, Schrappe M, Reiter A. Impact of cranial radiotherapy on central nervous system prophylaxis in children and adolescents with central nervous system-negative stage III or IV lymphoblastic lymphoma. J Clin Oncol. 2006b;24:491–499. - PubMed

Publication types